GLP-1s in Adolescents: The Evidence and the Debate

Extending GLP-1 medications to teenagers is one of the more genuinely difficult questions the field faces. The trial data exist and are reasonably encouraging on efficacy, but efficacy is not the whole conversation when the patient is still growing. This is a case where the evidence and the ethics deserve to be held together.

What the trials show

The anchor trial is STEP TEENS, led by Daniel Weghuber and published in The New England Journal of Medicine in 2022. It randomized 201 adolescents (ages 12 to under 18) with obesity to once-weekly semaglutide 2.4 mg or placebo for 68 weeks.

The efficacy was striking. Mean BMI fell 16.1% with semaglutide versus a 0.6% rise with placebo — a difference of about 16.7 percentage points. And 73% of teens on semaglutide lost at least 5% of body weight, compared with 18% on placebo. Shortly after, the FDA expanded Wegovy’s approval to include adolescents aged 12 and older. On the narrow question of “does it produce weight loss in teens,” the answer is reasonably clear: yes, and substantially.

The efficacy data in adolescents are strong — a roughly 16% BMI reduction over 68 weeks in STEP TEENS. The harder questions are about long-term safety, growth, and the wider context of treating a still-developing person.

What clinicians actually weigh

The debate is not really about whether the drugs work in this group. It is about everything around that.

The considerations in play

• Long-term safety. Multi-year and longer exposure data in a developing body are limited, which is a real and acknowledged unknown.
• Duration of treatment. If obesity is chronic and these drugs work while taken, adolescent use implies the prospect of very long-term therapy, with all the open questions that raises.
• Alternatives and context. How drug therapy fits alongside lifestyle, family, and behavioral support, rather than replacing it, is central to responsible use.
• The cost of untreated obesity. On the other side of the ledger, adolescent obesity carries real health consequences, and withholding effective treatment is not a neutral act either.

Reasonable clinicians weigh these against each other, and they do not all land in the same place. That disagreement reflects genuine uncertainty, not carelessness.

The takeaway

GLP-1 medications produce meaningful weight loss in adolescents — STEP TEENS showed a ~16% BMI reduction over 68 weeks, and the FDA has approved semaglutide for teens 12 and older. That part of the evidence is solid. The honest bottom line is that the real debate lives in the unknowns: long-term safety in a developing body, the implications of potentially lifelong therapy, and how drug treatment fits within broader care. This is appropriately a careful, individualized, specialist decision, and anyone presenting it as obviously simple in either direction is flattening a genuinely hard question.

Sources

• Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS, New England Journal of Medicine, 2022)